









Markets
/
Stocks
/
nasdaq-lenz
/

LENZ Therapeutics Inc

LENZ



View Detailed Chart

16.890USD

-0.730-4.14%

Close 12/23, 16:00（ET）Quotes delayed by 15 min

482.86MMarket Cap

LossP/E TTM



LENZ Therapeutics Inc

16.890

-0.730-4.14%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-4.14%

5 Days

-1.11%

1 Month

-42.86%

6 Months

-43.59%

Year to Date

-41.50%

1 Year

-48.24%

View Detailed Chart

TradingKey Stock Score of LENZ Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

LENZ Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

208 / 501

Overall Ranking

365 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

52.571

Target Price

+96.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

LENZ Therapeutics Inc Highlights

StrengthsRisks

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

Undervalued

The company’s latest PE is -19.24, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 30.36M shares, increasing 3.24% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 14.61K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.11.